Cerebral DARPP-32 expression after methylphenidate administration in young and adult rats

International Journal of Developmental Neuroscience

Volumn 27, Issue 1, 2009, Pages 1-7

  Souza, Renan P ^a   Soares, Eliane C ^a   Rosa, Daniela V F ^a   Souza, Bruno R ^a   Gomes, Karin M ^b   Valvassori, Samira S ^b   Réus, Gislaine Z ^b   Inácio, Cecília G ^b   Martins, Márcio R ^b   Gomez, Marcus V ^a   Quevedo, João ^b   Romano Silva, Marco A ^a  

^a Faculdade de Medicina   (Brazil)

^b UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

DARPP 32; Methylphenidate; Molecular aging changes; Protein expression; Rat brain; Western blot

Indexed keywords

METHYLPHENIDATE; PHOSPHOPROTEIN DARPP 32;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; DRUG EFFECT; GROUPS BY AGE; HIPPOCAMPUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

AGING; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBRAL CORTEX; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DRUG ADMINISTRATION SCHEDULE; HIPPOCAMPUS; METHYLPHENIDATE; RATS; UP-REGULATION;

RATTUS;

EID: 58249092611     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2008.11.001     Document Type: Article

References (51)

1. Aickin M., and Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs. Holm methods. Am. J. Public Health 86 (1996) 726-728
2. Albert K.A., Hemmings H.C., Adamo A.I., Potkin S.G., Akbarian S., Sandman C.A., Cotman C.W., Bunney W.E., and Greengard P. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch. Gen. Psychiatry 59 (2002) 705-712
3. Amenta F., Cavallotti C., De M.M., Ricci A., and Vega J.A. Changes of dopamine-sensitive cyclic AMP-generating system in the rat hippocampus as a function of age. Arch. Gerontol. Geriatr. 10 (1990) 279-285
4. Amenta F., Mignini F., Ricci A., Sabbatini M., Tomassoni D., and Tayebati S.K. Age-related changes of dopamine receptors in the rat hippocampus: a light microscope autoradiography study. Mech. Ageing Dev. 122 (2001) 2071-2083
5. Bangs M.E., Tauscher-Wisniewski S., Polzer J., Zhang S., Acharya N., Desaiah D., Trzepacz P.T., and Allen A.J. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J. Am. Acad. Child Adolesc. Psychiatry 47 (2008) 209-218
6. Barik S., and de B.R. Evidence for a functional role of the dopamine D3 receptors in the cerebellum. Brain Res. 737 (1996) 347-350
7. Castellanos F.X., and Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat. Rev. Neurosci. 3 (2002) 617-628
8. Fagundes A.O., Rezin G.T., Zanette F., Grandi E., Assis L.C., Dal-Pizzol F., Quevedo J., and Streck E.L. Chronic administration of methylphenidate activates mitochondrial respiratory chain in brain of young rats. Int. J. Dev. Neurosci. 25 (2007) 47-51
9. Feldcamp L.A., Souza R.P., Romano-Silva M., Kennedy J.L., and Wong A.H. Reduced prefrontal cortex DARPP-32 mRNA in completed suicide victims with schizophrenia. Schizophr. Res. 103 (2008) 192-200
10. Fukui R., Svenningsson P., Matsuishi T., Higashi H., Nairn A.C., Greengard P., and Nishi A. Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice. J. Neurochem. 87 (2003) 1391-1401
11. Gerasimov M.R., Franceschi M., Volkow N.D., Gifford A., Gatley S.J., Marsteller D., Molina P.E., and Dewey S.L. Comparison between intraperitoneal and oral methylphenidate administration: a microdialysis and locomotor activity study. J. Pharmacol. Exp. Ther. 295 (2000) 51-57
12. Gomes K.M., Petronilho F.C., Mantovani M., Garbelotto T., Boeck C.R., Dal-Pizzol F., and Quevedo J. Antioxidant enzyme activities following acute or chronic methylphenidate treatment in young rats. Neurochem. Res. 33 (2007) 1024-1027
13. Henry D.J., Hu X.T., and White F.J. Adaptations in the mesoaccumbens dopamine system resulting from repeated administration of dopamine D1 and D2 receptor-selective agonists: relevance to cocaine sensitisation. Psychopharmacology (Berl) 140 (1998) 233-242
14. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Statist. 6 (1979) 65-70
15. Kalivas P.W., and Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Brain Res. Rev. 16 (1991) 223-244
16. Kuribara H., and Uchihashi Y. Effects of haloperidol on the methamphetamine sensitization: assessment by ambulatory activity in mice. Jpn. J. Psychiatry Neurol. 47 (1993) 661-668
17. Leiner H.C., Leiner A.L., and Dow R.S. Reappraising the cerebellum: what does the hindbrain contribute to the forebrain?. Behav. Neurosci. 103 (1989) 998-1008
18. Mannuzza S., Klein R.G., Bessler A., Malloy P., and LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch. Gen. Psychiatry 50 (1993) 565-576
19. Martins M.R., Reinke A., Petronilho F.C., Gomes K.M., Dal-Pizzol F., and Quevedo J. Methylphenidate treatment induces oxidative stress in young rat brain. Brain Res. 1078 (2006) 189-197
20. Meng Z.H., Feldpaush D.L., and Merchant K.M. Clozapine and haloperidol block the induction of behavioral sensitization to amphetamine and associated genomic responses in rats. Brain Res. Mol. Brain Res. 61 (1998) 39-50
21. Meririnne E., Kankaanpaa A., and Seppala T. Rewarding properties of methylphenidate: sensitization by prior exposure to the drug and effects of dopamine D1- and D2-receptor antagonists. J. Pharmacol. Exp. Ther. 298 (2001) 539-550
22. Middleton F.A., and Strick P.L. Cerebellar projections to the prefrontal cortex of the primate. J. Neurosci. 21 (2001) 700-712
23. Nally R.E., McNamara F.N., Clifford J.J., Kinsella A., Tighe O., Croke D.T., Fienberg A.A., Greengard P., and Waddington J.L. Topographical assessment of ethological and dopamine receptor agonist-induced behavioral phenotype in mutants with congenic DARPP-32 'Knockout'. Neuropsychopharmacology 28 (2003) 2055-2063
24. Pereyra-Munoz N., Rugerio-Vargas C., ngoa-Perez M., Borgonio-Perez G., and Rivas-Arancibia S. Oxidative damage in substantia nigra and striatum of rats chronically exposed to ozone. J. Chem. Neuroanat. 31 (2006) 114-123
25. Reis H.J., Rosa D.V., Guimaraes M.M., Souza B.R., Barros A.G., Pimenta F.J., Souza R.P., Torres K.C., and Romano-Silva M.A. Is DARPP-32 a potential therapeutic target?. Expert Opin. Ther. Targets 11 (2007) 1649-1661
26. Ricci A., Zaccheo D., and Amenta F. Identification of age-related changes of dopamine D1-like receptors in the rat cerebellar cortex. Synapse 21 (1995) 37-44
27. Rosa D.V., Souza R.P., Souza B.R., Motta B.S., Caetano F., Jornada L.K., Feier G., Jeromin A., Gomez M.V., Quevedo J., and Romano-Silva M.A. NCS-1 expression in rat brain after electroconvulsive stimulation. Neurochem. Res. 32 (2007) 81-85
28. Rosa D.V., Souza R.P., Souza B.R., Motta B.S., Caetano F., Jornada L.K., Feier G., Gomez M.V., Quevedo J., and Romano-Silva M.A. DARPP-32 expression in rat brain after electroconvulsive stimulation. Brain Res. 1179 (2007) 35-41
29. Rosa D.V., Souza R.P., Souza B.R., Guimaraes M.M., Carneiro D.S., Valvassori S.S., Gomez M.V., Quevedo J., and Romano-Silva M.A. DARPP-32 expression in rat brain after an inhibitory avoidance task. Neurochem. Res. 33 (2008) 2257-2262
30. Seeman P., and Madras B.K. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol. Psychiatry 3 (1998) 386-396
31. Shaw P., Eckstrand K., Sharp W., Blumenthal J., Lerch J.P., Greenstein D., Clasen L., Evans A., Giedd J., and Rapoport J.L. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 19649-19654
32. Souza R.P., Rosa D.V., Souza B.R., and Romano-Silva M.A. DARPP-32. AFCS Signal. Gateway (2006) 10.1038/mp.a000752.01
33. Souza R.P., Soares E.C., Rosa D.V., Souza B.R., Reus G.Z., Barichello T., Gomes K.M., Gomez M.V., Quevedo J., and Romano-Silva M.A. Methylphenidate alters NCS-1 expression in rat brain. Neurochem. Int. 53 (2008) 12-16
34. Souza R.P., Romano-Silva M.A., Lieberman J.A., Meltzer H.Y., Wong A.H., and Kennedy J.L. Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) 200 (2008) 177-186
35. Stroppolo A., Guinea B., Tian C., Sommer J., and Ehrlich M.E. Role of phosphatidylinositide 3-kinase in brain-derived neurotrophic factor-induced DARPP-32 expression in medium size spiny neurons in vitro. J. Neurochem. 79 (2001) 1027-1032
36. Svenningsson P., Tzavara E.T., Carruthers R., Rachleff I., Wattler S., Nehls M., McKinzie D.L., Fienberg A.A., Nomikos G.G., and Greengard P. Diverse psychotomimetics act through a common signaling pathway. Science 302 (2003) 1412-1415
37. Tarazi F.I., Tomasini E.C., and Baldessarini R.J. Postnatal development of dopamine D1-like receptors in rat cortical and striatolimbic brain regions: an autoradiographic study. Dev. Neurosci. 21 (1999) 43-49
38. Tropea T.F., Kosofsky B.E., and Rajadhyaksha A.M. Enhanced CREB and DARPP-32 phosphorylation in the nucleus accumbens and CREB, ERK, and GluR1 phosphorylation in the dorsal hippocampus is associated with cocaine-conditioned place preference behavior. J. Neurochem. 106 (2008) 1780-1790
39. Tukey J.W. Comparing individual means in the analysis of variance. Biometrics 5 (1949) 99-114
40. Valvassori S.S., Frey B.N., Martins M.R., Reus G.Z., Schimidtz F., Inacio C.G., Kapczinski F., and Quevedo J. Sensitization and cross-sensitization after chronic treatment with methylphenidate in adolescent Wistar rats. Behav. Pharmacol. 18 (2007) 205-212
41. Vanderschuren L.J., and Kalivas P.W. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) 151 (2000) 99-120
42. Venero J.L., de la R.C., Machado A., and Cano J. Age-related changes on monoamine turnover in hippocampus of rats. Brain Res. 631 (1993) 89-96
43. Viggiano D., Ruocco L.A., and Sadile A.G. Dopamine phenotype and behaviour in animal models: in relation to attention deficit hyperactivity disorder. Neurosci. Biobehav. Rev. 27 (2003) 623-637
44. Volkow N.D., Fowler J.S., Wang G.J., Logan J., Schlyer D., MacGregor R., Hitzemann R., and Wolf A.P. Decreased dopamine transporters with age in health human subjects. Ann. Neurol. 36 (1994) 237-239
45. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., Hitzemann R., and Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 155 (1998) 1325-1331
46. Volkow N.D., Fowler J.S., Wang G., Ding Y., and Gatley S.J. Mechanism of action of methylphenidate: insights from PET imaging studies. J. Atten. Disord. 6 Suppl. 1 (2002) S31-S43
47. Volkow N.D., Wang G.J., Fowler J.S., and Ding Y.S. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol. Psychiatry 57 (2005) 1410-1415
48. Walaas S.I., Aswad D.W., and Greengard P. A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature 301 (1983) 69-71
49. Wilens T.E., and Biederman J. The stimulants. Psychiatr. Clin. North Am. 15 (1992) 191-222
50. Wilens T.E., Spencer T.J., and Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J. Atten. Disord. 5 (2002) 189-202
51. Zachariou V., Sgambato-Faure V., Sasaki T., Svenningsson P., Berton O., Fienberg A.A., Nairn A.C., Greengard P., and Nestler E.J. Phosphorylation of DARPP-32 at Threonine-34 is required for cocaine action. Neuropsychopharmacology 31 (2006) 555-562